Drugs Controller General of India (DCGI) News

ZyCov-D vaccine has been tested on adults as well as children above 12 years of age and the regulatory body experts are satisfied with the results. ZyCov-D is likely to receive an emergency nod from DCGI in the next few days.

DCGI has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct a clinical trial of Colchicine on COVID-19 patients. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.

The DCGI on Saturday gave emergency approved to DRDO's drug 2-deoxy-D-glucose (2-DG). The clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients.

The approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night. Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa. The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its first application to the DCGI on July 25.